15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial

Lukas Bethlehem / nature - Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the sam…

AI Summary: A randomized phase 1b trial compared a defined 15‑strain live biotherapeutic product with traditional donor fecal microbiota transplant for recurrent Clostridioides difficile infection and found comparable safety and efficacy. The result supports a manufactured, standardized microbiome therapy as a realistic alternative to donor stool, simplifying logistics and regulation — and making “poop pills” slightly less artisanal.